Hot Spotlight

Sosei Heptares has been renamed Nxera Pharma, with updates made to its corporate structure

28 April 2024
3 min read

On March 27th, Sosei Group Corporation of Japan announced that during the 34th Annual General Meeting held in Tokyo on the same day, followed by a subsequent board meeting, the reelection of the company’s board members and executives was approved. Additionally, the Annual General Meeting approved a "partial amendment to the corporate charter (change of company name)." With this approval, the company will be renamed Nxera Pharma Corporation starting April 1, 2024.

The name "Nxera" is derived from the words "Next" and "Era," intended to express the company’s determination to be a leader in a new era of science and medical advancement, as stated in the press release. The mission of the new company is to be "a technology-driven pharmaceutical enterprise devoted to breaking the status quo and providing better treatment options for patients across multiple therapeutic areas."

Business Overview

图形用户界面, 应用程序

描述已自动生成

图片包含 文本

描述已自动生成

Drug Discovery + Drug Development and Commercialization: The European site is responsible for basic research and early-stage drug discovery, while the sites in Japan and South Korea primarily handle the clinical development of drugs.

图形用户界面, 文本, 应用程序

描述已自动生成

Based on high-quality clinical data from Japan, we are conducting clinical development for our internal projects. Simultaneously, the company is also bringing some U.S.-approved drugs to Japan for Phase III clinical studies, using this as a platform to reach the Asian market.

图示

描述已自动生成

Financial Performance

Overall, the financial data for 2023 shows a decline compared to both 2021 and 2022. It is worth mentioning that in 2023, there were no new out-licensing deals in GPCR drug discovery, the area where the Sosei Hectares team excels. Regarding milestone payment revenues, there was a significant reduction in 2023, partly due to the failure of clinical studies for several GLP-1 small molecule agonists developed in collaboration with Pfizer.

图形用户界面, 应用程序

描述已自动生成

R&D pipeline

Focusing on potential GPCR targets, the Nxera team has continuously excelled in driving the development of innovative small molecule drugs using a structure-based drug discovery approach.

图形用户界面, 文本, 应用程序

描述已自动生成

Targeting GPR52 for the development of clinical candidates in schizophrenia is the only new transfer project of the Nxera team after 2022.

New projects advanced into clinical research and development include the EP4 antagonist, EP4 agonist project, and the GPR52 agonist project.

图示, 文本

描述已自动生成

Stable GPCR Research and Development Platform

图形用户界面, 应用程序, 表格

描述已自动生成

图示

描述已自动生成

图形用户界面, 图表

描述已自动生成

Representative drugs

The company's first commercially marketed drug, PIVLAZ® (a selective ETA receptor antagonist), has made a significant impact on stroke treatment in Japan and accumulated real-world evidence. PIVLAZ® has been recommended by the Japanese Stroke Society and proven to effectively treat subarachnoid hemorrhage (SAH). It can prevent delayed cerebral ischemia and poor outcomes with high-level evidence, thus enhancing the confidence of neurosurgeons in prescribing this medication.

图形用户界面, 应用程序

描述已自动生成

Daridorexant is a dual orexin receptor antagonist that blocks the binding and activity of the wakefulness-promoting neuropeptide orexin. At the end of 2023, a New Drug Application for daridorexant was submitted in Japan for the treatment of insomnia, with an anticipated market launch in Japan in the fourth quarter of 2024.

图形用户界面, 应用程序

描述已自动生成

Cenerimod is an S1PR1 receptor modulator currently in Phase III clinical trials for the treatment of Systemic Lupus Erythematosus (SLE).

表格

中度可信度描述已自动生成

2024 Strategic Objectives

The key strategic goals set for the fiscal year 2024 include executing at least one major partnership, initiating at least one internal Phase 1 study, and acquiring/licensing at least one late-stage drug applicable to Japan and the Asia-Pacific region (excluding China).

图形用户界面, 文本, 应用程序

描述已自动生成

FDA Prioritizes GSK's Proposal to Expand Jemperli Use with Chemotherapy in Advanced Endometrial Cancer
Latest Hotspot
3 min read
FDA Prioritizes GSK's Proposal to Expand Jemperli Use with Chemotherapy in Advanced Endometrial Cancer
28 April 2024
FDA has prioritized GSK’s submission to broaden the use of Jemperli (dostarlimab) with chemotherapy for treating all adult patients with initial advanced or relapsed endometrial cancer.
Read →
Breakthrough in Parkinson's Treatment: Positive Phase 3 Trial Results for Cerevel's Tavapadon
Hot Spotlight
2 min read
Breakthrough in Parkinson's Treatment: Positive Phase 3 Trial Results for Cerevel's Tavapadon
28 April 2024
On April 18th, Cerevel reported positive results from its Phase 3 TEMPO-3 trial for tavapadon, a D1/D5 receptor partial agonist aimed at treating Parkinson's disease.
Read →
Alkermes has started the Vibrance-1 Phase 2 trial to assess ALKS 2680 for treating Narcolepsy Type 1
Latest Hotspot
3 min read
Alkermes has started the Vibrance-1 Phase 2 trial to assess ALKS 2680 for treating Narcolepsy Type 1
28 April 2024
Alkermes plc has launched the Vibrance-1 study, a phase 2 clinical trial aimed at assessing the safety and effectiveness of ALKS 2680 versus a placebo in individuals diagnosed with type 1 narcolepsy.
Read →
What is Triple-Negative Breast Cancer?
"What" Series
2 min read
What is Triple-Negative Breast Cancer?
28 April 2024
Triple-Negative Breast Cancer (TNBC) is a subtype of breast cancer that lacks estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER-2) on its cells.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.